Interestingly, the chronic pharmacologic blockade of MCT1 by CHC can decrease the tumor cell oxygen consumption and delay the tumor growth in the mouse models of lung cancer and the human colorectal adenocarcinoma cell line [188], whereas the antitumor efficacy is restricted to expressing MCT1 located at the plasma membrane of carcinoma cells [188]. Here, SLC16A1 is linked to carcinoma.